Progress in myelodysplastic syndromes.
During the past 5 years, we have witnessed an explosion in our understanding, classification, and number of therapeutic opportunities for patients with myelodysplastic syndromes (MDS). These include the development of new histologic classifications, scoring systems, supportive care measures, and most importantly, effective treatments that are safe and can modify the natural history of this complex group of hematopoietic disorders. In this brief review, and as part of the Leukemia 2008, Fourth International Conference, held in Houston during September 2008, I summarize some of the most important recent developments in the field of MDS and try to identify new problems and opportunities for patients and researchers in this area.
Garcia-Manero
Guillermo
G
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. ggarciam@mdanderson.org
D000368:Aged; D000375:Aging; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D044127:Epigenesis, Genetic; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008495:Medical Oncology / Q000379:methods*; D008875:Middle Aged; D009154:Mutation; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D012306:Risk; D016896:Treatment Outcome
D004791:Enzyme Inhibitors